In Quiet Debut, Alzheimer's Drug Finds Questions, Skepticism

The first new Alzheimer’s treatment in more than 20 years was hailed as a breakthrough when regulators approved it more than four months ago, but its rollout...

Related Keywords

Rhode Island ,United States ,Boston ,Massachusetts ,Dallas ,Texas ,Washington ,Los Angeles ,Stephen Salloway ,Maha Radhakrishnan ,Brendan Kelley ,Salim Syed ,Wendy Van Fossen ,Neurology Center ,Ut Southwestern Medical Center ,Japan Eisai Co ,Science Department ,Drug Administration ,Cleveland Clinic ,Mass General Brigham ,Mizuho Securities United ,Medical Center ,Van Fossen ,Biogen Chief Medical Officer ,Zaldy Tan ,Medicare Advantage ,Associated Press Health ,Howard Hughes Medical Institute ,Aduhelm ,Alzheimer 039 S ,Alzheimer 039s Disease ,Alzheimer 039s Drug ,Biogen ,Fda ,Eurology ,The Cleveland Clinic ,